No Data
Pharma Block Sciences (300725): Short-term profitability under pressure, orders continue to show a positive trend.
Summary: Short-term profitability under pressure, orders continue to improve, bullish on long-term growth prospects. Investment Highlights: Maintain a "shareholding" rating. 2024Q1-Q3 revenue of 1.128 billion yuan, down 12.67% year-on-year, net income attributable to parent
Pharma Block Sciences (300725.SZ): In 2024, the company's Nanjing research and other production sites have relatively high capacity utilization rates.
On October 31, Gleonhui reported that pharma block sciences (300725.SZ) held a performance briefing on October 30, 2024, regarding "What is the utilization rate of company's production capacity?" The company stated that in 2024, the utilization rates of production capacity at the Nanjing research and other production sites are relatively high. The decline in revenue is mainly due to price reductions. In terms of production volume, there was a significant increase in production volume in the first three quarters of 2024.
Pharma Block Sciences (300725.SZ): Currently, the overall order backlog is mainly composed of orders from European and American customers, accounting for about 70%.
Pharma Block Sciences (300725.SZ) held an earnings conference on October 30, 2024, to discuss the "Company's CDMO order structure." The company stated that currently, the overall outstanding orders are mainly from European and American customers, accounting for about 70%, with the Asia-Pacific and Japan-Korea region accounting for about 30%. In terms of project types, early-stage projects dominate, while late-stage projects have a lower proportion. Over the past two years, as customers have further recognized the company's business capabilities and projects have progressed to later stages, the number of projects entering Phases II and III in the CDMO business has been continuously increasing. It is expected that in another 1-2 years, late-stage projects will
Pharma Block Sciences (300725.SZ): The amount of orders in hand at the end of June increased by 20% year-on-year.
Pharma block sciences (300725.SZ) held a performance briefing on October 30, 2024, regarding "Splitting and delivery rhythm of company orders?" The company stated that the amount of orders on hand at the end of June increased by 20% year-on-year, and this positive trend has been maintained in the third quarter. Currently, the company's orders are mainly concentrated on projects in the early stages. The delivery period for non-spot molecular segment projects is generally 2-3 months; for APIs, even in the early stages of the project, the delivery period requires 4-5 months, and the delivery period for API in the later stage is even longer.
Yakshi Technology: Report for the third quarter of 2024
Pharma Block Sciences (300725.SZ) released its performance for the first three quarters, with a net income of 0.132 billion yuan, a decrease of 14.45%.
Pharma Block Sciences (300725.SZ) released the third quarter report for 2024, with the company's revenue for the first three quarters reaching 1...
No Data
No Data